Andy Hsieh
Stock Analyst at William Blair
(4.11)
# 1,609
Out of 4,421 analysts
326
Total ratings
43.9%
Success rate
8%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $30.38 | - | 37 | Jun 9, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | n/a | $44.51 | - | 10 | Jun 8, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | n/a | $1.21 | - | 17 | Jun 3, 2026 | |
| LNTH Lantheus Holdings | Maintained: Buy | n/a | $103.86 | - | 14 | Jun 3, 2026 | |
| TNYA Tenaya Therapeutics | Maintained: Buy | n/a | $0.7306 | - | 4 | Jun 3, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | n/a | $8.26 | - | 15 | Jun 1, 2026 | |
| KLRA Kailera Therapeutics | Maintained: Buy | n/a | $19.90 | - | 3 | May 27, 2026 | |
| AARD Aardvark Therapeutics | Reiterated: Buy | n/a | $3.93 | - | 5 | May 15, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Hold | n/a | $2.03 | - | 9 | May 14, 2026 | |
| ALT Altimmune | Reiterated: Hold | n/a | $2.70 | - | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.36 | - | 8 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $6.76 | - | 27 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.7073 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $20.77 | - | 12 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $60.98 | - | 30 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $51.91 | -15.24% | 57 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $24.09 | +32.84% | 1 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $44.75 | - | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.662173 | - | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.03 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.62 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $123.76 | n/a | 1 | Feb 12, 2019 |
Viking Therapeutics
Jun 9, 2026
Reiterated: Buy
Price Target: n/a
Current: $30.38
Upside: -
Structure Therapeutics
Jun 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $44.51
Upside: -
Cardiff Oncology
Jun 3, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.21
Upside: -
Lantheus Holdings
Jun 3, 2026
Maintained: Buy
Price Target: n/a
Current: $103.86
Upside: -
Tenaya Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: n/a
Current: $0.7306
Upside: -
Corbus Pharmaceuticals Holdings
Jun 1, 2026
Maintained: Buy
Price Target: n/a
Current: $8.26
Upside: -
Kailera Therapeutics
May 27, 2026
Maintained: Buy
Price Target: n/a
Current: $19.90
Upside: -
Aardvark Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.93
Upside: -
Pyxis Oncology
May 14, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.03
Upside: -
Altimmune
May 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.70
Upside: -
May 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.36
Upside: -
May 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $6.76
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.7073
Upside: -
May 11, 2026
Reiterated: Hold
Price Target: n/a
Current: $20.77
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $60.98
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: $44
Current: $51.91
Upside: -15.24%
Apr 29, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $24.09
Upside: +32.84%
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $44.75
Upside: -
Aug 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $0.662173
Upside: -
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $1.03
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $1.62
Upside: n/a
Feb 12, 2019
Maintained: Buy
Price Target: n/a
Current: $123.76
Upside: n/a